Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Bocchia

Showing results (1-10 of 280) with videos related to

Pageof 28
Sort By:
Haematologica|July 2, 2002
Is there any role left for p210-derived peptide vaccines in chronic myeloid leukemia?Monica Bocchia
Reviews on Recent Clinical Trials|November 24, 2021
Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical TrialsAlessandro Gozzetti, Monica Bocchia
Journal of Personalized Medicine|September 23, 2022
Steps towards a Multiple Myeloma Cure?Alessandro Gozzetti, Monica Bocchia
Oncology Research|June 12, 2023
Liquid biopsy and blood-based minimal residual disease evaluation in multiple myelomaAlessandro Gozzetti, Monica Bocchia
Expert Opinion on Emerging Drugs|October 27, 2006
Emerging drugs in chronic myelogenous leukaemiaMonica Bocchia, Francesco Forconi, Francesco Lauria
Annals of Hematology|July 15, 2009
Cutaneous myeloma and bortezomibAlessandro Gozzetti, Marzia Defina, Monica Bocchia
Clinical Lymphoma, Myeloma & Leukemia|December 4, 2014
Central nervous system multiple myelomaAlessandro Gozzetti, Alfonso Cerase, Monica Bocchia
Leukemia|September 4, 2020
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19Alessandro Gozzetti, Enrico Capochiani, Monica Bocchia
Cancers|February 25, 2022
CD26/DPP-4 in Chronic Myeloid LeukemiaAnna Sicuranza, Donatella Raspadori, Monica Bocchia
Annals of Hematology|January 9, 2016
Central nervous system multiple myelomaAlessandro Gozzetti, Alfonso Cerase, Monica Bocchia
Pageof 28

Showing results (1-10 of 280) with videos related to

Sort By:
Pageof 28
Haematologica|July 2, 2002
Is there any role left for p210-derived peptide vaccines in chronic myeloid leukemia?Monica Bocchia
Reviews on Recent Clinical Trials|November 24, 2021
Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical TrialsAlessandro Gozzetti, Monica Bocchia
Journal of Personalized Medicine|September 23, 2022
Steps towards a Multiple Myeloma Cure?Alessandro Gozzetti, Monica Bocchia
Oncology Research|June 12, 2023
Liquid biopsy and blood-based minimal residual disease evaluation in multiple myelomaAlessandro Gozzetti, Monica Bocchia
Expert Opinion on Emerging Drugs|October 27, 2006
Emerging drugs in chronic myelogenous leukaemiaMonica Bocchia, Francesco Forconi, Francesco Lauria
Annals of Hematology|July 15, 2009
Cutaneous myeloma and bortezomibAlessandro Gozzetti, Marzia Defina, Monica Bocchia
Clinical Lymphoma, Myeloma & Leukemia|December 4, 2014
Central nervous system multiple myelomaAlessandro Gozzetti, Alfonso Cerase, Monica Bocchia
Leukemia|September 4, 2020
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19Alessandro Gozzetti, Enrico Capochiani, Monica Bocchia
Cancers|February 25, 2022
CD26/DPP-4 in Chronic Myeloid LeukemiaAnna Sicuranza, Donatella Raspadori, Monica Bocchia
Annals of Hematology|January 9, 2016
Central nervous system multiple myelomaAlessandro Gozzetti, Alfonso Cerase, Monica Bocchia
Pageof 28